Skip to main content
Premium Trial:

Request an Annual Quote

Nuvectis Begins Phase I Trial of HSF1 Inhibitor in ARID1a-Mutant Solid Tumors

NEW YORK – Nuvectis Pharma on Friday began a Phase I trial of its HSF1 inhibitor NXP800 involving patients with biomarker-defined advanced ovarian and endometrial cancer.

The dose escalation part of the Phase I study will enroll patients with advanced solid tumors. In the dose expansion part of the study, researchers will enroll patients with ARID1a-mutated ovarian clear cell carcinoma and endometrioid carcinoma, along with other ARID1a-mutated solid tumors.

In preclinical studies, NXP800 showed anti-proliferative activity in a range of cancer cell lines. In studies using human xenograft models, the drug inhibited tumor growth in ARID1a-mutated ovarian clear cell carcinoma and endometrioid carcinoma. NXP800 uses synthetic lethality mechanisms to target tumor cells.

In August, Nuvectis licensed NXP800 from oncology investment firm CRT Pioneer Fund. The drug was discovered by the Cancer Research UK Cancer Therapeutics Unit at the Institute of Cancer Research in London. Also in August, Nuvectis raised $15 million in a Series A funding round to advance NXP800 into clinical trials.

The company, based in Fort Lee, New Jersey, also licensed an SRC/YES1 inhibitor discovered by the University of Edinburgh in Scotland last year. That drug, dubbed NXP900, is in preclinical development.